CA3032618A1 - Liquid oral gastrointestinal delivery system of purified cannabinoids using vitamin e tpgs - Google Patents
Liquid oral gastrointestinal delivery system of purified cannabinoids using vitamin e tpgs Download PDFInfo
- Publication number
- CA3032618A1 CA3032618A1 CA3032618A CA3032618A CA3032618A1 CA 3032618 A1 CA3032618 A1 CA 3032618A1 CA 3032618 A CA3032618 A CA 3032618A CA 3032618 A CA3032618 A CA 3032618A CA 3032618 A1 CA3032618 A1 CA 3032618A1
- Authority
- CA
- Canada
- Prior art keywords
- vitamin
- tpgs
- cannabinoids
- thc
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This disclosure relates to new methods for delivering an aqueous cannabinoid solution orally for absorption through the gastrointestinal tract. The composition includes 1) active forms of cannabinoids and/or purified cannabinoids, 2) Vitamin E TPGS and 3) Water. The self-emulsifying composition decreases Hepatic First Pass Metabolism and increases absorption of cannabinoids. The composition increases shelf stability and even distribution of Cannabinoids throughout the solution, improving upon previous oral, aqueous cannabinoid delivery solutions.
Description
Classification A61K9/107 - Emulsions/ Micelles A61K31/355 - Tocopherols A61K9/4858 - Organic compounds A61K9/08 - Solutions Synonyms Vitamin E TPGS
TPGS
d-a tocopheryl polyethylene glycol 1000 succinate Tocopheryl Polyethylene Glycol Succinate.
Description Technical Field This disclosure relates to the cannabis industry. In particular, this disclosure relates to water-soluble cannabinoid formulations, including methods for creating said water-soluble cannabinoid formulations.
This disclosure relates generally to a delivery system to improve the administration of cannabinoids and standardized Cannabis extracts through a self-emulsifying drug delivery system, which optimizes cannabinoid dissolution properties, decreases hepatic first-pass metabolism and increases absorption, thereby enhancing bioavailability through the gastrointestinal tract.
Background The word "cannabis" refers to a genus of flowering plants. Plants of genus cannabis include several species, including Cannabis Sativa, Cannabis Indica, and Cannabis Ruderalis.
Can nabinoids are of particular interest for research and commercialization.
Most extractions of cannabis plant matter aim to extract cannabinoids, particularly tetrahydrocannabinol (THC) and Cannabidiol(CBD). THC is useful for relieving pain, treating glaucoma and relieving nausea.
THC is also gaining immense popularity as a recreational drug substance.
Usually, cannabinoids are extracted from the cannabis plant as part of a crude mixture, further refined and combined with other chemical compounds found in the cannabis plant. Other Cannabinoids of interest are CBG (Cannabigerol) and CBN (Cannabinol).
Current methods of administration cannabinoids fail to take full advantage of cannabinoid properties. For example, burning plant matter and inhaling the vapour does not allow for selection of certain cannabinoids for their certain desired benefit. One can choose a plant with certain known properties, e.g., THC content, but there is still little to no control over selecting individual cannabinoids. Inhaling smoke also leads to many harmful and toxic compounds introduced into the body. Current oral liquid delivery technologies have slow onset to due poor absorption, long offset times due to hydrophobic nature of cannabinoids and have a bitter taste.
There exists a need for new cannabinoid formulations. In particular, there exists a need for water-soluble cannabinoid formulations. Additionally, there exists a need for methods for producing aqueous cannabinoid formulations. Furthermore, there exists a need for making formulations with increased permeability into the bloodstream. There also exists a need for cannabis formulations which provide increased bioavailability of cannabinoids.
This offers a faster onset time for patients and more accurate dosing for recreational consumers.
The oral liquid delivery technology allows the hydrophobic nature of cannabis oil and distillate to be altered into a hydrophilic state which improves flavour profile, absorption time and in a precise dosing mechanism.
Detailed Description Unless specifically indicated otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. In addition, any method or material similar or equivalent to a method or material described herein can be used in the practice of the present invention. For purposes of the present invention, the following terms are defined. The term "cannabis"
refers to plants of the genus cannabis, including cannabis sativa, cannabis indica, and cannabis ruderalis.
The term "cannabinoid" refers to a chemical compound that shows direct or indirect activity at a cannabinoid receptor. There are two main cannabinoid receptors, CNR1 (also known as CBI) and CNR2 (also known as CB2). Other receptors that research suggests have cannabinoid activity include the GPR55, GPR18, and TRPVI receptors. The term "phytocannabinoid" refers to cannabinoids that occur in a plant species or are derived from cannabinoids occurring in a plant species. Examples of cannabinoids include, but are not limited to, tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), and cannabigerol monomethyl ether (CBGM).tetrahydrocannabinol, A9-tetrahydrocannabinol(THC), A8-tetrahydrocannabinol, standardized marijuana extracts, A8-tetrahydrocannabinol-DM H, tetrahydrocannabinol propyl propyl analogue (THCV), 11 -hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, 5'-azido-A8-tetrahydrocannabinol, AMG-1, AMG-3, AM411, AM708, AM836, AM855, AM919, AM926, AM938, cannabidiol(CBD), cannabidiol propyl analogue(CBDV), cannabinol (CBN), cannabichromene (CBC), cannabichromene propyl analogue, cannabigerol (CBG), cannabicyclol (CBL), cannabielsoin (CBE), cannabinodiol (CBDL), and cannabitriol (CBTL), CF 47497, CF 55940, CF 55244, CF 50556, CT-3 or IP-751 (ajulemic acid), dimethylheptyl HHC, HU-210, HU-211, HU-308, WIN 55212-2, desacetyl-L-nantradol, dexanabinol, JWH-051, JWH-133, levonantradol, L-759633, nabilone, 0-1184, cannabicyclohexanol (CP-47,497 C8 homolog), 10-hydroxycannabidiol, l',2',3',4',5'-pentanorcannabino1-3-carboxylic acid, l'-hydroxycannabinol, 11-hydroxycannabinol, 9- carboxy-1 1-norcannabinol, l'-oxocannabino1,11-nor-A8-THC-9-carboxylic acid, 2'-carboxy-3',4',5'-trinor-A9-THC, 5'-carboxy-A9-THC, 9-carboxy-11-nor-A9-THC, 9-carboxy-II-nor-A8- THC, [(6aR,10aR)-3-[(IS,2R)-1,2-dimethylheptyl]-6a,7,10,10a-tetrahydro-6, 6,9-trimethy1-6H-dibenzo[b,d]pyran-l-ol], 9-carboxy-1 1-nor- (2 or 4)-chloro-A8-THC, 8a-II-dihydroxy-A9-THC, 8[3-1 I-Dihydroxy-A9-THC, 5'-Dimethylamino-A8-THC, 11-hydroxy-A9-THC, l'-hydroxy-A9-THC
(Isomer B), I 1-hydroxy-A8-THC, 2'-hydroxy-A9-THC, 3'-hydroxy-A9-THC, 4'-hydroxy-A9- THC, 5'-hydroxy-1i9-THC, 8a-hydroxy-A9-THC, 8I3-hydroxy-A9-THC, 5'-methylamino-A8-THC, 5'-N-methyl-N-4-(7-nitrobenzofurazano)amino-A8-THC, (-)-trans-A8-THC, 5'-trimethylammonium-A8-THC phenolate, 5'-Trimethylammonium-11-hydroxy-A8-THC
phenolate, and mixtures thereof;
The term "distillate" refers to a solution that has been concentrated by any known means of evaporation or distillation of the cannabis plant that is in a purified state.
As used herein, the term "purified" means isolated from the plant using chromatography, distillation, extractions, or similar technique resulting in a greater than 60% purity. In some embodiments the "purified" compositions disclosed herein are greater than 70%
purity. In some embodiments the "purified" compositions disclosed herein are greater than 80%
purity. In some embodiments the "purified" compositions disclosed herein are greater than 90%
purity.
0029] THC/CBD: 0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0030] CBD/THC:0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0031] THC/CBN:0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0032] CBN/THC: 0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0033] CBD/CBN:0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0034] CBN/CBD: 0:1- 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0035] THC/CBD/CBN: 1-99% THC: 1-99% CBD : 1-99% CBN.
The term "vitamin E" refers to a group of compounds that include both tocopherols and tocotrienols including, but not limited to a-tocopherol, [3-tocopherol, y-tocopherol, 6- tocopherol, a-tocotrienol, f3-tocotrienol, y-tocotrienol, 6-tocotrienol, salts thereof, and combinations thereof.
Vitamin E can be obtained from sources including, but not limited, to soybeans, sunflowers, and combinations thereof.
Disclosed herein are new cannabinoid formulations, including water-soluble cannabinoid formulations. In one embodiment, the formulations disclosed herein are used for creating other new formulations. In one embodiment, the formulations disclosed herein are soluble in other liquids, e.g., aqueous liquids such as juices, soft drinks, coffee, tea, etc.
and can be used as an active ingredient in dry foods.
In some embodiments, the method further comprises mixing a quantity of vitamin E with the extract to produce a cannabis oil composition. Disclosed herein are methods of making formulations with increased permeability into the bloodstream. Also disclosed herein are cannabis formulations, which provide increased bioavailability of cannabinoids. Disclosed herein is a new composition comprising a first purified cannabinoid and Vitamin E
TPGS.
Example 1 The following examples illustrate certain aspects of the above-described invention. They should not be read as limiting the full scope of the invention.
The cannabis distillate and vitamin E TPGS is heated to 600 for 15 minutes separately and then combine until homogenous at 65C. The vitamin E is 4 parts to one part of cannabis oil. Water is then brought to 70C. The mixture of purified cannabis and Vitamin E TPGS is than slowly added to the water while stirring, continuing to stir until cloudy dispersion becomes clear while maintaining a temperature above 65C. Remove heat and continue to stir at room temperature for 2 hours to ensure complete uniformity.
TPGS
d-a tocopheryl polyethylene glycol 1000 succinate Tocopheryl Polyethylene Glycol Succinate.
Description Technical Field This disclosure relates to the cannabis industry. In particular, this disclosure relates to water-soluble cannabinoid formulations, including methods for creating said water-soluble cannabinoid formulations.
This disclosure relates generally to a delivery system to improve the administration of cannabinoids and standardized Cannabis extracts through a self-emulsifying drug delivery system, which optimizes cannabinoid dissolution properties, decreases hepatic first-pass metabolism and increases absorption, thereby enhancing bioavailability through the gastrointestinal tract.
Background The word "cannabis" refers to a genus of flowering plants. Plants of genus cannabis include several species, including Cannabis Sativa, Cannabis Indica, and Cannabis Ruderalis.
Can nabinoids are of particular interest for research and commercialization.
Most extractions of cannabis plant matter aim to extract cannabinoids, particularly tetrahydrocannabinol (THC) and Cannabidiol(CBD). THC is useful for relieving pain, treating glaucoma and relieving nausea.
THC is also gaining immense popularity as a recreational drug substance.
Usually, cannabinoids are extracted from the cannabis plant as part of a crude mixture, further refined and combined with other chemical compounds found in the cannabis plant. Other Cannabinoids of interest are CBG (Cannabigerol) and CBN (Cannabinol).
Current methods of administration cannabinoids fail to take full advantage of cannabinoid properties. For example, burning plant matter and inhaling the vapour does not allow for selection of certain cannabinoids for their certain desired benefit. One can choose a plant with certain known properties, e.g., THC content, but there is still little to no control over selecting individual cannabinoids. Inhaling smoke also leads to many harmful and toxic compounds introduced into the body. Current oral liquid delivery technologies have slow onset to due poor absorption, long offset times due to hydrophobic nature of cannabinoids and have a bitter taste.
There exists a need for new cannabinoid formulations. In particular, there exists a need for water-soluble cannabinoid formulations. Additionally, there exists a need for methods for producing aqueous cannabinoid formulations. Furthermore, there exists a need for making formulations with increased permeability into the bloodstream. There also exists a need for cannabis formulations which provide increased bioavailability of cannabinoids.
This offers a faster onset time for patients and more accurate dosing for recreational consumers.
The oral liquid delivery technology allows the hydrophobic nature of cannabis oil and distillate to be altered into a hydrophilic state which improves flavour profile, absorption time and in a precise dosing mechanism.
Detailed Description Unless specifically indicated otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. In addition, any method or material similar or equivalent to a method or material described herein can be used in the practice of the present invention. For purposes of the present invention, the following terms are defined. The term "cannabis"
refers to plants of the genus cannabis, including cannabis sativa, cannabis indica, and cannabis ruderalis.
The term "cannabinoid" refers to a chemical compound that shows direct or indirect activity at a cannabinoid receptor. There are two main cannabinoid receptors, CNR1 (also known as CBI) and CNR2 (also known as CB2). Other receptors that research suggests have cannabinoid activity include the GPR55, GPR18, and TRPVI receptors. The term "phytocannabinoid" refers to cannabinoids that occur in a plant species or are derived from cannabinoids occurring in a plant species. Examples of cannabinoids include, but are not limited to, tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), and cannabigerol monomethyl ether (CBGM).tetrahydrocannabinol, A9-tetrahydrocannabinol(THC), A8-tetrahydrocannabinol, standardized marijuana extracts, A8-tetrahydrocannabinol-DM H, tetrahydrocannabinol propyl propyl analogue (THCV), 11 -hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, 5'-azido-A8-tetrahydrocannabinol, AMG-1, AMG-3, AM411, AM708, AM836, AM855, AM919, AM926, AM938, cannabidiol(CBD), cannabidiol propyl analogue(CBDV), cannabinol (CBN), cannabichromene (CBC), cannabichromene propyl analogue, cannabigerol (CBG), cannabicyclol (CBL), cannabielsoin (CBE), cannabinodiol (CBDL), and cannabitriol (CBTL), CF 47497, CF 55940, CF 55244, CF 50556, CT-3 or IP-751 (ajulemic acid), dimethylheptyl HHC, HU-210, HU-211, HU-308, WIN 55212-2, desacetyl-L-nantradol, dexanabinol, JWH-051, JWH-133, levonantradol, L-759633, nabilone, 0-1184, cannabicyclohexanol (CP-47,497 C8 homolog), 10-hydroxycannabidiol, l',2',3',4',5'-pentanorcannabino1-3-carboxylic acid, l'-hydroxycannabinol, 11-hydroxycannabinol, 9- carboxy-1 1-norcannabinol, l'-oxocannabino1,11-nor-A8-THC-9-carboxylic acid, 2'-carboxy-3',4',5'-trinor-A9-THC, 5'-carboxy-A9-THC, 9-carboxy-11-nor-A9-THC, 9-carboxy-II-nor-A8- THC, [(6aR,10aR)-3-[(IS,2R)-1,2-dimethylheptyl]-6a,7,10,10a-tetrahydro-6, 6,9-trimethy1-6H-dibenzo[b,d]pyran-l-ol], 9-carboxy-1 1-nor- (2 or 4)-chloro-A8-THC, 8a-II-dihydroxy-A9-THC, 8[3-1 I-Dihydroxy-A9-THC, 5'-Dimethylamino-A8-THC, 11-hydroxy-A9-THC, l'-hydroxy-A9-THC
(Isomer B), I 1-hydroxy-A8-THC, 2'-hydroxy-A9-THC, 3'-hydroxy-A9-THC, 4'-hydroxy-A9- THC, 5'-hydroxy-1i9-THC, 8a-hydroxy-A9-THC, 8I3-hydroxy-A9-THC, 5'-methylamino-A8-THC, 5'-N-methyl-N-4-(7-nitrobenzofurazano)amino-A8-THC, (-)-trans-A8-THC, 5'-trimethylammonium-A8-THC phenolate, 5'-Trimethylammonium-11-hydroxy-A8-THC
phenolate, and mixtures thereof;
The term "distillate" refers to a solution that has been concentrated by any known means of evaporation or distillation of the cannabis plant that is in a purified state.
As used herein, the term "purified" means isolated from the plant using chromatography, distillation, extractions, or similar technique resulting in a greater than 60% purity. In some embodiments the "purified" compositions disclosed herein are greater than 70%
purity. In some embodiments the "purified" compositions disclosed herein are greater than 80%
purity. In some embodiments the "purified" compositions disclosed herein are greater than 90%
purity.
0029] THC/CBD: 0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0030] CBD/THC:0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0031] THC/CBN:0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0032] CBN/THC: 0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0033] CBD/CBN:0:1 - 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0034] CBN/CBD: 0:1- 1:0- 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1 etc., [0035] THC/CBD/CBN: 1-99% THC: 1-99% CBD : 1-99% CBN.
The term "vitamin E" refers to a group of compounds that include both tocopherols and tocotrienols including, but not limited to a-tocopherol, [3-tocopherol, y-tocopherol, 6- tocopherol, a-tocotrienol, f3-tocotrienol, y-tocotrienol, 6-tocotrienol, salts thereof, and combinations thereof.
Vitamin E can be obtained from sources including, but not limited, to soybeans, sunflowers, and combinations thereof.
Disclosed herein are new cannabinoid formulations, including water-soluble cannabinoid formulations. In one embodiment, the formulations disclosed herein are used for creating other new formulations. In one embodiment, the formulations disclosed herein are soluble in other liquids, e.g., aqueous liquids such as juices, soft drinks, coffee, tea, etc.
and can be used as an active ingredient in dry foods.
In some embodiments, the method further comprises mixing a quantity of vitamin E with the extract to produce a cannabis oil composition. Disclosed herein are methods of making formulations with increased permeability into the bloodstream. Also disclosed herein are cannabis formulations, which provide increased bioavailability of cannabinoids. Disclosed herein is a new composition comprising a first purified cannabinoid and Vitamin E
TPGS.
Example 1 The following examples illustrate certain aspects of the above-described invention. They should not be read as limiting the full scope of the invention.
The cannabis distillate and vitamin E TPGS is heated to 600 for 15 minutes separately and then combine until homogenous at 65C. The vitamin E is 4 parts to one part of cannabis oil. Water is then brought to 70C. The mixture of purified cannabis and Vitamin E TPGS is than slowly added to the water while stirring, continuing to stir until cloudy dispersion becomes clear while maintaining a temperature above 65C. Remove heat and continue to stir at room temperature for 2 hours to ensure complete uniformity.
Claims (13)
1. A method of formulating an aqueous cannabis concentrate. The method comprising: 1) a purified Cannabinoid, 2) Vitamin E TPGS to produce a concentrate, dispersing the concentrate into an aqueous solution, wherein the concentrate becomes water soluble.
2. A composition, comprising: a first purified cannabinoid; Vitamin E TPGS and Water.
The composition of claim 1 , comprising a ratio of Vitamin E TPGS to the purified cannabinoid of about 1000:1 to about 5:1 by percent mass.
The composition of claim 1 , comprising a ratio of Vitamin E TPGS to the purified cannabinoid of about 1000:1 to about 5:1 by percent mass.
3. The composition of claim 1 , comprising water.
4. The composition of claim 1 , comprising Vitamin E TPGS.
5. The composition of claim 4, comprising a micelle.
6. The composition of claim 1 , comprising a purified Cannabinoid 0-10% mass
7. A method of claim 1, wherein a purified cannabinoid is heated to 40C to
8. A method of claim 1, wherein Vitamin E TPGS is heated to 40C to 100C
9. A method of claim 1, A purified Cannabinoid and Vitamin E TPGS are combined until homogeneous for 1 minute to 1 hour.
10. A method of claim 1, heating water to 50C to 100C
11. A method of claim 14, where cliam 14 and 15 are mixed for 15 minutes to 24 hours
12. A method of claim 14, where the particle size is 20nm to 250nm
13. The method of claim 14, wherein the component is a liquid, or the component is a gel having a viscosity between 0.3 centipoise and 250,000 centipoise.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3032618A CA3032618A1 (en) | 2019-02-04 | 2019-02-04 | Liquid oral gastrointestinal delivery system of purified cannabinoids using vitamin e tpgs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3032618A CA3032618A1 (en) | 2019-02-04 | 2019-02-04 | Liquid oral gastrointestinal delivery system of purified cannabinoids using vitamin e tpgs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3032618A1 true CA3032618A1 (en) | 2020-08-04 |
Family
ID=71946854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3032618A Abandoned CA3032618A1 (en) | 2019-02-04 | 2019-02-04 | Liquid oral gastrointestinal delivery system of purified cannabinoids using vitamin e tpgs |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA3032618A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021109823A1 (en) * | 2019-12-06 | 2021-06-10 | 汉义生物科技（北京）有限公司 | Cannabinoid nanomicelle preparation and method for preparing same |
| WO2023159277A1 (en) * | 2022-02-28 | 2023-08-31 | Emyria | Cannabinoid dosage form |
-
2019
- 2019-02-04 CA CA3032618A patent/CA3032618A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021109823A1 (en) * | 2019-12-06 | 2021-06-10 | 汉义生物科技（北京）有限公司 | Cannabinoid nanomicelle preparation and method for preparing same |
| WO2023159277A1 (en) * | 2022-02-28 | 2023-08-31 | Emyria | Cannabinoid dosage form |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200138772A1 (en) | Stabilized formulations of cannabinoid compositions | |
| Hong et al. | Phytoestrogenic compounds in alfalfa sprout (Medicago sativa) beyond coumestrol | |
| CN109789124A (en) | Cannabis composition | |
| CA3076963A1 (en) | Liquid dosage forms comprising cannabis, methods of making and use | |
| US20210274814A1 (en) | Infusion of emulsified hydrophobic active ingredients into high polyphenolic beverages | |
| CA3117809A1 (en) | Polymer-based oral cannabinoid and/or terpene formulations | |
| US20150126754A1 (en) | Cannabis plant isolate comprising delta-9-tetrahydrocannabinol and a method for preparing such an isolate | |
| JP2012527453A (en) | Method for producing nutritional supplement composition and nutritional supplement produced by the production method | |
| CA3032618A1 (en) | Liquid oral gastrointestinal delivery system of purified cannabinoids using vitamin e tpgs | |
| GB2597170A (en) | Diluents for compositions of cannabinoids and uses thereof | |
| WO2022013854A1 (en) | Oral cannabinoid compositions | |
| US20220370379A1 (en) | Cannabinoid-containing additive and method therefor | |
| WO2021046628A1 (en) | Stable medicinal cannabidiol compositions | |
| Farias Azevedo et al. | Polymeric nanoparticle systems loaded with red propolis extract: a comparative study of the encapsulating systems, PCL-Pluronic versus Eudragit® E100-Pluronic | |
| Han et al. | Incidental nanoparticles in black tea infusion: Carriers of bioactives fortifying protection on intestinal mucosal cells against oxidative stresses | |
| Silva et al. | Health benefits of nongallated and gallated flavan-3-ols: A prospectus | |
| CA3115116A1 (en) | Ultrapure phenol compositions | |
| Papas | Vitamin E TPGS and its applications in nutraceuticals | |
| EP3782602A1 (en) | Composition with enhanced passenger molecule loading for use in a method for administration | |
| CN111991444A (en) | Solubilizing carrier composition for cannabis oil and solubilized cannabis oil solid dispersion | |
| US20200188323A1 (en) | Composition With Enhanced Passenger Molecule Loading | |
| IL262050A (en) | Compositions for treating hemorrhoids | |
| US11497727B2 (en) | System and method for making cannabinoid nanoparticle carrier composition | |
| US20200268708A1 (en) | Formulation for nasal delivery of cannabinoids | |
| US20230210786A1 (en) | Method for solubilizing natural, endogenous and synthetic cannabinoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220804 |
|
| FZDE | Discontinued |
Effective date: 20220804 |